Firebrick Pharma Ltd has released a press release.
Firebrick Receives $1.08m R&D Tax Incentive
Filed with ASX ·
6ix hasn’t read this filing yet.
Firebrick Pharma Limited on 6ix
Earlier from Firebrick Pharma
- September 2022 Quarterly Activity Report & Appendix 4C
- Appendix 4E & Annual Report
- June 2022 Quarterly Activity Report & Appendix 4C
- Outcome of s60 appeal for Nasodine and next steps
- Firebrick starts Phase 3 common cold trial of Nasodine
Later from Firebrick Pharma
- Nasodine Composition Patent Accepted in Australia
- December 2022 Quarterly Activity Report & Appendix 4C
- Appendix 4D & Half Yearly Report and Accounts
- FRE files EU Paediatric Investigation Plan for Nasodine
- Firebrick Pharmas Phase 3 Trial of Nasodine Resumes
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma